Access Denied

We’re proud to share that ICON is the only CRO named a 2027 BioSpace Best Place to Work, placing in the Top 10 in the large employer category. This recognition reflects the views of life sciences professionals and consi...

ADCs have broad potential as targeted cancer therapies, but predicting which patients will benefit is a significant challenge. A single ADC combines three therapeutic components whose efficacy is then shaped by the tumor...

Emerging approaches to first-in-human studies are helping sponsors obtain meaningful clinical insights sooner through integrated study designs, stronger patient engagement, and strategic biomarker implementation. In thi...

As understanding of multi-system disease grows, so does interest in earlier disease intervention. However, development and commercialisation pathways for early-intervention therapies remain complex and challenging. Learn...

Complex clinical supply models shouldn’t be designed only for the ideal pathway. For cell and gene therapy studies, a delay, identity mismatch, condition issue, failed manufacture or unavailable interface can affect an i...

Staying up to date with global regulatory changes can be challenging. ICON's Global Regulatory Intelligence Newsletter brings together the latest updates from regulatory authorities around the world in a concise, easy-t...

Latest issue out now. Regulatory requirements continue to evolve across global markets. Keeping pace with changes from the FDA, EMA, MHRA, PMDA, NMPA and other health authorities is critical for successful product deve...

New research published in Drug Metabolism and Disposition offers important insights into the clinical pharmacology of remibrutinib, an oral, highly selective BTK inhibitor approved in the United States, China, the Europe...

How do you accelerate enrolment without sacrificing retention? Watch our on-demand webinar to explore practical strategies for maintaining study momentum whilst protecting participant engagement and retention in today’s ...

Biosimilar regulation is changing, accelerating competition and reshaping what it takes to succeed in the biologics market. In our latest blog, Kimberly Salgado & Lauren Zalin from ICON’s Centre for Biosimilar Drug Deve...

Recent changes to biosimilar regulation are accelerating competition and changing the strategic priorities of biologic manufacturers. In our latest blog, experts from ICON’s Centre for Biosimilar Drug Development explor...

Endometriosis innovation is accelerating across therapeutics, diagnostics, biomarkers and digital health. But translating that progress into clinical development requires joined-up thinking across study design, evidence ...